MRI: Development of an Integrated Image-guided Thermal Therapy Platform

博斯曼1337438由来自堪萨斯州立大学三所学院的五名研究人员组成的团队将开发一个完全集成的图像引导热疗平台，方法是设计一个射频(RF)热疗单元，并将其集成到600 MHz核磁共振Bruker Avance IIITM高性能数字核磁共振光谱仪中。斯特凡·博斯曼(化学)将担任这项工作的协调PI。建议的仪器将是第一个高场(14T)系统，能够成像在射频热疗过程中小动物的生理效应和温度分布。这将使纳米颗粒增强的射频热疗在细胞介导的治疗中具有前所未有的敏感度，从而实现靶向、监测和反馈控制。由于核磁共振和磁共振成像设备在技术上的相似之处，由此产生的技术最终将使个性化热疗成为可能，用于治疗动物和人类的传染病和癌症。开发人员团队的高度跨学科性质将促进工程、艺术和科学学院与兽医学院之间的快速技术转移。尽管热疗在治疗多种疾病方面具有巨大的潜力，但由于技术障碍，其潜力尚未得到充分开发。一个完全集成的图像引导热疗平台将提供一种简单的方法，将热疗用作单一疗法，并与其他疗法(如细胞疗法或放射疗法)协同使用。热疗平台将通过参与的学院、堪萨斯大学癌症中心、堪萨斯州立大学的特里·C·约翰逊癌症中心、堪萨斯州立大学的纳米技术创新中心(www.NICKS.edu)以及美国国土安全部新兴和人畜共患动物疾病卓越中心(CEEZAD，http://www.ceezad.org/))提供给研究界。与国家生物和农业防御设施(NBAF)的合作将在其开始运作后立即开始。

Bossmann1337438A team of five investigators from three colleges of Kansas State University will develop a fully integrated image-guided thermal therapy platform by designing a radio-frequency (RF-) hyperthermia unit and integrating it into a 600MHz NMR Bruker AVANCE IIITM High Performance Digital NMR Spectrometer. Stefan Bossmann (Chemistry) will serve as coordinating PI of this endeavor. The proposed instrumentation will be the first high field (14 T) system capable of imaging the physiological effects and temperature distribution in small animals during RF-hyperthermia treatment. This will permit targeting, monitoring and feedback-control of nanoparticle-enhanced RF hyperthermia in cell-mediated therapies with unprecedented sensitivity. Due to the technical similarities of NMR and Magnetic Resonance Imaging devices, the resulting technology will eventually enable personalized hyperthermia treatment for treating infectious diseases and cancers in animals and humans. The highly interdisciplinary nature of the team of developers will facilitate rapid technology transfer between the Colleges of Engineering, Arts and Sciences and Veterinary Medicine. Although hyperthermia has great potential for the treatment of numerous disorders, its full potential has not been explored because of technical obstacles. A fully integrated image-guided thermal therapy platform will provide atraightforward approach to the utilization of hyperthermia as monotherapy and in synergy with other therapies, such as cytotherapy or radiation therapy. The thermal therapy platform will be made available to the research community through the participating colleges, the University of Kansas Cancer Center (UKCC), the Terry C. Johnson Cancer Center at Kansas State, the Nanotechnology Innovation Center of Kansas State (www.NICKS.edu), and the U.S. Department of Homeland Security Center of Excellence for Emerging and Zoonotic Animal Diseases (CEEZAD, http://www.ceezad.org/) at Kansas State. Collaboration with The National Bio- and Agro-Defense Facility (NBAF) will begin as soon as it is operational.